SEC Form 4 · accession 0001621608-15-000001
Immunoclin Corp · IMCL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Khadija Benlhassan
Officer — Chief Scientific Officer · Director
Period of report
Jun 10, 2015
Accepted (ET)
Jun 12, 2015 · 12:34 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001520047
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 10, 2015 | A | 2,000,000 | $5.00 | A | 4,000,000 | I | Held by KBLH Holding BV, a company which Dr. Benlhassan has voting and investment control over |
| Series A Preferred Stock | holding | — | — | — | 100,000 | I | Held by KBLH Holding BV, a company which Dr. Benlhassan has voting and investment control over |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock Options | $1.45 | holding | — | — | — | Nov 1, 2014 | Nov 1, 2019 | Common Stock | 1,000,000 | 1,000,000 | I |